-+ 0.00%
-+ 0.00%
-+ 0.00%

Boundless Bio starts Phase 1 KOMODO-1 trial of BBI-940 in breast cancer

PUBT·04/17/2026 20:50:02
Listen to the news
Boundless Bio starts Phase 1 KOMODO-1 trial of BBI-940 in breast cancer
  • Boundless Bio flagged new preclinical breast cancer data for lead ecDNA-directed therapy BBI-940, an oral kinesin degrader now in Phase 1 KOMODO-1 trial (NCT07408089).
  • Results will be presented April 21, 2026 at AACR Annual Meeting in a late-breaking poster session.
  • Data show BBI-940 drove antitumor activity in validated breast cancer models, with strongest effects in tumors characterized by extrachromosomal DNA.
  • Company positioned findings as support for ongoing first-in-human development in advanced or metastatic ER+/HER2- breast cancer, with additional evaluation in TNBC-LAR.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604171649PRIMZONEFULLFEED9692378) on April 17, 2026, and is solely responsible for the information contained therein.